Target Gene/Pathway Pathway / Gene

---

Search results

---

No.	KEGG PATHWAY On map, Yellow: Drug target, Red: All disease-related	KEGG GENES	KEGG DRUG	DrugBank	Disease ID
1	Arrhythmogenic right ventricular cardiomyopathy 💬	[1] ITGA4 💬 Arrhythmogenic right ventricular cardiomyopathy × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Arrhythmogenic right ventricular cardiomyopathy × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 1. Arrhythmogenic right ventricular cardiomyopathy × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
2	Cell adhesion molecules 💬	[1] ITGA4 💬 Cell adhesion molecules × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Cell adhesion molecules × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 2. Cell adhesion molecules × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
3	Cell adhesion molecules 💬	[1] PDCD1 💬 Cell adhesion molecules × Name Full Name PDCD1 programmed cell death 1	Pembrolizumab 💬 Cell adhesion molecules × Name Other Names Pembrolizumab Pembrolizumab (USAN) Pembrolizumab (genetical recombination) (JAN) Keytruda (TN) KEYTRUDA	Pembrolizumab	[2] 25, 285 💬 3. Cell adhesion molecules × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 285 Fanconi anemia;
4	Coronavirus disease - COVID-19 💬	[2] IFNAR1, IFNAR2 💬 Coronavirus disease - COVID-19 × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Coronavirus disease - COVID-19 × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 4. Coronavirus disease - COVID-19 × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
5	Coronavirus disease - COVID-19 💬	[2] IFNAR1, IFNAR2 💬 Coronavirus disease - COVID-19 × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Coronavirus disease - COVID-19 × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 5. Coronavirus disease - COVID-19 × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
6	Cytokine-cytokine receptor interaction 💬	[1] CSF3R 💬 Cytokine-cytokine receptor interaction × Name Full Name CSF3R colony stimulating factor 3 receptor	Filgrastim 💬 Cytokine-cytokine receptor interaction × Name Other Names Filgrastim Filgrastim (USP/INN) Filgrastim (genetical recombination) (JP18) Filgrastim (genetical recombination) [Filgrastim biosimilar 1] (JAN) Tbo-filgrastim Filgrastim (genetical recombination) [Filgrastim biosimilar 2] (JAN) Filgrastim (genetical recombination) [Filgrastim biosimilar 3] (JAN) Filgrastim-sndz Filgrastim-aafi Neupogen (TN) Nivestym (TN) Grastofil (TN) Zarxio (TN) GRANIX NEUPOGEN NIVESTYM NYPOZI RELEUKO ZARXIO	Filgrastim	[29]  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 6. Cytokine-cytokine receptor interaction × Disease ID Name  2  Amyotrophic lateral sclerosis;ALS;  6  Parkinson disease;Disease Parkinson's; 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 26 HTLV-1-associated myelopathy;Tropical spastic paraparesis;HTLV-1;HTLV-I;HAM; 28 Systemic amyloidosis;Immunoglobulin light chain amyloidosis;Amyloid light-chain amyloidosis;AL amyloidosis;Immunoglobulin light chain amyloidosis;Immunoglobulin-related amyloidosis;Amyloid heavy-chain amyloidosis;Amyloid heavy-chain amyloidosis;AH amyloidosis;Systemic wild-type transthyretin amyloidosis;Senile systemic amyloidosis;SSA;Hereditary transthyretin amyloidosis;Familial amyloidosis;Familial amyloid polyneuropathy;FAP;Hereditary systemic amyloidosis; 34 Neurofibromatosis;Neurofibromatosis type 1;NF1;Recklinghausen disease;Neurofibromatosis type 2;NF2; 35 Pemphigus; 38 Stevens-Johnson syndrome;SJS;Mucocutaneous ocular syndrome; 40 Takayasu arteritis;Aortitis syndrome;Pulseless disease;Aortitis syndrome; 41 Giant cell arteritis;Temporal arteritis; 42 Polyarteritis nodosa;PAN; 45 Eosinophilic granulomatosis with Polyangiitis;EGPA;Eosinophilic multiple vasculitis granulomatous disease;Allergic granulomatous angiitis;AGA;Churg-Strauss syndrome;CSS; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 47 Buerger disease;Thromboangiitis obliterans; 49 Systemic lupus erythematosus;SLE; 51 Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc; 60 Aplastic anemia; 62 Paroxysmal nocturnal hemoglobinuria;PNH; 65 Primary immunodeficiency;X-linked severe combined immunodeficiency;X-SCID;Reticular dysgenesis;Adenosine deaminase deficiency;Omenn syndrome;Purine nucleoside phosphorylase deficiency;CD8 deficiency;ZAP-70 deficiency;MHC class I deficiency;MHC class II deficiency;Other combined immunodeficiencies;Wiskott-Aldrich syndrome;WAS;Ataxia telangiectasia;Nijmegen breakage syndrome;Bloom syndrome;Immunodeficiency, centromere region instability, facial anomalies syndrome;ICF syndrome;PMS2 deficiency;Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome;RIDDLE syndrome;Schimke syndrome;Netherton syndrome;Thymic hypoplasia;DiGeorge syndrome;22q11.2 deletion syndrome;Hyper-IgE syndrome;Hepatic venoocclusive immunodeficiency;Immunodeficiency with central hepatic vein atresia;Dyskeratosis congenita;X-linked agammaglobulinaemia;Common variable immunodeficiency;Hyper-IgM syndrome;Isolated IgG subclass deficiency;Selective IgA deficiency;Specific antibody production deficiency;Infant transient hypogammaglobulinemia;Other predominantly antibody deficiencies;Chédiak-Higashi syndrome;Chediak-Higashi syndrome;X-linked lymphoproliferative syndrome;SAP deficiency;SH2D1A/SLAM-associated protein deficiency;XIAP deficiency;X-linked inhibitor of apoptosis deficiency;Autoimmune lymphoproliferative syndrome;ALPS;Other diseases of immune dysregulation;Familial hemophagocytic syndrome;FHPS;Familial hemophagocytic lymphohistiocytosis;FHL;Perforin deficiency;Munc13-4 deficiency;Syntaxin 11 deficiency;Munc18-2 deficiency;Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;APECED;Autoimmune polyglandular syndrome;APS;Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome;IPEX syndrome;CD25 deficiency;ITCH deficiency;Severe congenital neutropenia;Cyclic neutropenia;Other congenital defects of neutrophil function;p14 deficiency;Glycogen storage disease type Ib;Leukocyte adhesion deficiency;Shwachman-Diamond syndrome;Chronic granulomatous disease;Myeloperoxidase deficiency;Mendelian susceptibility to mycobacterial disease;MSMD;Other congenital defects of phagocyte function;Anhidrotic ectodermal dysplasia with immunodeficiency;EDA-ID;Interleukin-1 receptor-associated kinase-4 deficiency;IRAK4 deficiency;MyD88 deficiency;Chronic mucocutaneous candidiasis;Other defects in innate immunity;Warts, hypogammaglobulinemia, infections, myelokathexis syndrome;WHIM syndrome;Congenital complement deficiency;C1q deficiency;C1r deficiency;C1s deficiency;C2 deficiency;C3 deficiency;C4 deficiency;C5 deficiency;C6 deficiency;C7 deficiency;C8 deficiency;C9 deficiency;Hereditary angioedema;C1 inhibitor deficiency;Inherited deficiency of complement system;Factor D deficiency;Factor I deficiency;Factor H deficiency;Properdin deficiency;MASP1 deficiency;MASP2 deficiency;3MC syndrome;Immunodeficiency associated with FCN3 mutation;FCN3; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD; 113 Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy; 164 Oculocutaneous albinism;Hermansky-Pudlak syndrome;HPS;Chediak-Higashi syndrome;Chédiak-Higashi syndrome;CHS;Griscelli syndrome; 256 Muscle glycogenosis;Muscular glycogenosis;Muscle glycogen storage disease;Muscular glycogen storage disease;Glycogen storage disease type 0;GSD0;Glycogen synthase deficiency;Glycogen storage disease type II;GSDII;Pompe disease;Alpha-1,4-glucosidase acid deficiency;Glycogen storage disease type III;GSDIII;Cori disease;Forbes disease;Glycogen debranching enzyme deficiency;Glycogen storage disease type IV;GSDIV;Andersen disease;Glycogen-branching enzyme deficiency;GBED;Glycogen storage disease type V;GSDV;McArdle disease;Muscle phosphorylase deficiency;Muscular phosphorylase deficiency;Glycogen storage disease type VII;GSDVII;Tarui disease;Phosphofructokinase deficiency;PFK deficiency;Glycogen storage disease type IXd;GSDIXd;Phosphorylase kinase deficiency;Phosphoglycerate kinase deficiency;PGK deficiency;Glycogen storage disease type X;GSDX;Phosphoglycerate mutase deficiency;Glycogen storage diseass type XI;GSDXI;Kanno disease;Lactate dehydrogenase deficiency;Glycogen storage diseass type XII;GSDXII;Aldolase A deficiency;Glycogen storage diseass type XIII;GSDXIII;Beta-enolase deficiency;Glycogen storage diseass type XIV;GSDXIV;Phosphoglucomutase deficiency;Glycogen storage diseass type XV;GSDXV;Glycogenin 1 deficiency; 283 Acquired pure red cell aplasia;Pure red cell aplasia; 284 Diamond-Blackfan anemia; 285 Fanconi anemia; 296 Biliary atresia; 331 Idiopathic multicentric castleman disease;iMCD;Castleman disease;
7	Cytokine-cytokine receptor interaction 💬	[2] IFNAR1, IFNAR2 💬 Cytokine-cytokine receptor interaction × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Cytokine-cytokine receptor interaction × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 7. Cytokine-cytokine receptor interaction × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
8	Cytokine-cytokine receptor interaction 💬	[2] IFNAR1, IFNAR2 💬 Cytokine-cytokine receptor interaction × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Cytokine-cytokine receptor interaction × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 8. Cytokine-cytokine receptor interaction × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
9	Cytoskeleton in muscle cells 💬	[1] ITGA4 💬 Cytoskeleton in muscle cells × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Cytoskeleton in muscle cells × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 9. Cytoskeleton in muscle cells × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
10	Dilated cardiomyopathy 💬	[1] ITGA4 💬 Dilated cardiomyopathy × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Dilated cardiomyopathy × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 10. Dilated cardiomyopathy × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
11	ECM-receptor interaction 💬	[1] ITGA4 💬 ECM-receptor interaction × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 ECM-receptor interaction × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 11. ECM-receptor interaction × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
12	Epstein-Barr virus infection 💬	[2] IFNAR1, IFNAR2 💬 Epstein-Barr virus infection × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Epstein-Barr virus infection × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 12. Epstein-Barr virus infection × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
13	Epstein-Barr virus infection 💬	[2] IFNAR1, IFNAR2 💬 Epstein-Barr virus infection × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Epstein-Barr virus infection × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 13. Epstein-Barr virus infection × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
14	Focal adhesion 💬	[1] ITGA4 💬 Focal adhesion × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Focal adhesion × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 14. Focal adhesion × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
15	Hematopoietic cell lineage 💬	[1] CSF3R 💬 Hematopoietic cell lineage × Name Full Name CSF3R colony stimulating factor 3 receptor	Filgrastim 💬 Hematopoietic cell lineage × Name Other Names Filgrastim Filgrastim (USP/INN) Filgrastim (genetical recombination) (JP18) Filgrastim (genetical recombination) [Filgrastim biosimilar 1] (JAN) Tbo-filgrastim Filgrastim (genetical recombination) [Filgrastim biosimilar 2] (JAN) Filgrastim (genetical recombination) [Filgrastim biosimilar 3] (JAN) Filgrastim-sndz Filgrastim-aafi Neupogen (TN) Nivestym (TN) Grastofil (TN) Zarxio (TN) GRANIX NEUPOGEN NIVESTYM NYPOZI RELEUKO ZARXIO	Filgrastim	[29]  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 15. Hematopoietic cell lineage × Disease ID Name  2  Amyotrophic lateral sclerosis;ALS;  6  Parkinson disease;Disease Parkinson's; 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 26 HTLV-1-associated myelopathy;Tropical spastic paraparesis;HTLV-1;HTLV-I;HAM; 28 Systemic amyloidosis;Immunoglobulin light chain amyloidosis;Amyloid light-chain amyloidosis;AL amyloidosis;Immunoglobulin light chain amyloidosis;Immunoglobulin-related amyloidosis;Amyloid heavy-chain amyloidosis;Amyloid heavy-chain amyloidosis;AH amyloidosis;Systemic wild-type transthyretin amyloidosis;Senile systemic amyloidosis;SSA;Hereditary transthyretin amyloidosis;Familial amyloidosis;Familial amyloid polyneuropathy;FAP;Hereditary systemic amyloidosis; 34 Neurofibromatosis;Neurofibromatosis type 1;NF1;Recklinghausen disease;Neurofibromatosis type 2;NF2; 35 Pemphigus; 38 Stevens-Johnson syndrome;SJS;Mucocutaneous ocular syndrome; 40 Takayasu arteritis;Aortitis syndrome;Pulseless disease;Aortitis syndrome; 41 Giant cell arteritis;Temporal arteritis; 42 Polyarteritis nodosa;PAN; 45 Eosinophilic granulomatosis with Polyangiitis;EGPA;Eosinophilic multiple vasculitis granulomatous disease;Allergic granulomatous angiitis;AGA;Churg-Strauss syndrome;CSS; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 47 Buerger disease;Thromboangiitis obliterans; 49 Systemic lupus erythematosus;SLE; 51 Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc; 60 Aplastic anemia; 62 Paroxysmal nocturnal hemoglobinuria;PNH; 65 Primary immunodeficiency;X-linked severe combined immunodeficiency;X-SCID;Reticular dysgenesis;Adenosine deaminase deficiency;Omenn syndrome;Purine nucleoside phosphorylase deficiency;CD8 deficiency;ZAP-70 deficiency;MHC class I deficiency;MHC class II deficiency;Other combined immunodeficiencies;Wiskott-Aldrich syndrome;WAS;Ataxia telangiectasia;Nijmegen breakage syndrome;Bloom syndrome;Immunodeficiency, centromere region instability, facial anomalies syndrome;ICF syndrome;PMS2 deficiency;Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome;RIDDLE syndrome;Schimke syndrome;Netherton syndrome;Thymic hypoplasia;DiGeorge syndrome;22q11.2 deletion syndrome;Hyper-IgE syndrome;Hepatic venoocclusive immunodeficiency;Immunodeficiency with central hepatic vein atresia;Dyskeratosis congenita;X-linked agammaglobulinaemia;Common variable immunodeficiency;Hyper-IgM syndrome;Isolated IgG subclass deficiency;Selective IgA deficiency;Specific antibody production deficiency;Infant transient hypogammaglobulinemia;Other predominantly antibody deficiencies;Chédiak-Higashi syndrome;Chediak-Higashi syndrome;X-linked lymphoproliferative syndrome;SAP deficiency;SH2D1A/SLAM-associated protein deficiency;XIAP deficiency;X-linked inhibitor of apoptosis deficiency;Autoimmune lymphoproliferative syndrome;ALPS;Other diseases of immune dysregulation;Familial hemophagocytic syndrome;FHPS;Familial hemophagocytic lymphohistiocytosis;FHL;Perforin deficiency;Munc13-4 deficiency;Syntaxin 11 deficiency;Munc18-2 deficiency;Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;APECED;Autoimmune polyglandular syndrome;APS;Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome;IPEX syndrome;CD25 deficiency;ITCH deficiency;Severe congenital neutropenia;Cyclic neutropenia;Other congenital defects of neutrophil function;p14 deficiency;Glycogen storage disease type Ib;Leukocyte adhesion deficiency;Shwachman-Diamond syndrome;Chronic granulomatous disease;Myeloperoxidase deficiency;Mendelian susceptibility to mycobacterial disease;MSMD;Other congenital defects of phagocyte function;Anhidrotic ectodermal dysplasia with immunodeficiency;EDA-ID;Interleukin-1 receptor-associated kinase-4 deficiency;IRAK4 deficiency;MyD88 deficiency;Chronic mucocutaneous candidiasis;Other defects in innate immunity;Warts, hypogammaglobulinemia, infections, myelokathexis syndrome;WHIM syndrome;Congenital complement deficiency;C1q deficiency;C1r deficiency;C1s deficiency;C2 deficiency;C3 deficiency;C4 deficiency;C5 deficiency;C6 deficiency;C7 deficiency;C8 deficiency;C9 deficiency;Hereditary angioedema;C1 inhibitor deficiency;Inherited deficiency of complement system;Factor D deficiency;Factor I deficiency;Factor H deficiency;Properdin deficiency;MASP1 deficiency;MASP2 deficiency;3MC syndrome;Immunodeficiency associated with FCN3 mutation;FCN3; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD; 113 Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy; 164 Oculocutaneous albinism;Hermansky-Pudlak syndrome;HPS;Chediak-Higashi syndrome;Chédiak-Higashi syndrome;CHS;Griscelli syndrome; 256 Muscle glycogenosis;Muscular glycogenosis;Muscle glycogen storage disease;Muscular glycogen storage disease;Glycogen storage disease type 0;GSD0;Glycogen synthase deficiency;Glycogen storage disease type II;GSDII;Pompe disease;Alpha-1,4-glucosidase acid deficiency;Glycogen storage disease type III;GSDIII;Cori disease;Forbes disease;Glycogen debranching enzyme deficiency;Glycogen storage disease type IV;GSDIV;Andersen disease;Glycogen-branching enzyme deficiency;GBED;Glycogen storage disease type V;GSDV;McArdle disease;Muscle phosphorylase deficiency;Muscular phosphorylase deficiency;Glycogen storage disease type VII;GSDVII;Tarui disease;Phosphofructokinase deficiency;PFK deficiency;Glycogen storage disease type IXd;GSDIXd;Phosphorylase kinase deficiency;Phosphoglycerate kinase deficiency;PGK deficiency;Glycogen storage disease type X;GSDX;Phosphoglycerate mutase deficiency;Glycogen storage diseass type XI;GSDXI;Kanno disease;Lactate dehydrogenase deficiency;Glycogen storage diseass type XII;GSDXII;Aldolase A deficiency;Glycogen storage diseass type XIII;GSDXIII;Beta-enolase deficiency;Glycogen storage diseass type XIV;GSDXIV;Phosphoglucomutase deficiency;Glycogen storage diseass type XV;GSDXV;Glycogenin 1 deficiency; 283 Acquired pure red cell aplasia;Pure red cell aplasia; 284 Diamond-Blackfan anemia; 285 Fanconi anemia; 296 Biliary atresia; 331 Idiopathic multicentric castleman disease;iMCD;Castleman disease;
16	Hematopoietic cell lineage 💬	[1] ITGA4 💬 Hematopoietic cell lineage × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Hematopoietic cell lineage × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 16. Hematopoietic cell lineage × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
17	Hepatitis B 💬	[1] IFNAR1 💬 Hepatitis B × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1	Interferon alfa 💬 Hepatitis B × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 17. Hepatitis B × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
18	Hepatitis B 💬	[1] IFNAR1 💬 Hepatitis B × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1	Interferon alfa-2b 💬 Hepatitis B × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 18. Hepatitis B × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
19	Hepatitis C 💬	[2] IFNAR1, IFNAR2 💬 Hepatitis C × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Hepatitis C × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 19. Hepatitis C × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
20	Hepatitis C 💬	[2] IFNAR1, IFNAR2 💬 Hepatitis C × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Hepatitis C × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 20. Hepatitis C × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
21	Herpes simplex virus 1 infection 💬	[2] IFNAR1, IFNAR2 💬 Herpes simplex virus 1 infection × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Herpes simplex virus 1 infection × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 21. Herpes simplex virus 1 infection × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
22	Herpes simplex virus 1 infection 💬	[2] IFNAR1, IFNAR2 💬 Herpes simplex virus 1 infection × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Herpes simplex virus 1 infection × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 22. Herpes simplex virus 1 infection × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
23	Human papillomavirus infection 💬	[2] IFNAR1, IFNAR2 💬 Human papillomavirus infection × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Human papillomavirus infection × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 23. Human papillomavirus infection × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
24	Human papillomavirus infection 💬	[2] IFNAR1, IFNAR2 💬 Human papillomavirus infection × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Human papillomavirus infection × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 24. Human papillomavirus infection × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
25	Human papillomavirus infection 💬	[1] ITGA4 💬 Human papillomavirus infection × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Human papillomavirus infection × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 25. Human papillomavirus infection × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
26	Hypertrophic cardiomyopathy 💬	[1] ITGA4 💬 Hypertrophic cardiomyopathy × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Hypertrophic cardiomyopathy × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 26. Hypertrophic cardiomyopathy × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
27	Influenza A 💬	[2] IFNAR1, IFNAR2 💬 Influenza A × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Influenza A × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 27. Influenza A × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
28	Influenza A 💬	[2] IFNAR1, IFNAR2 💬 Influenza A × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Influenza A × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 28. Influenza A × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
29	Intestinal immune network for IgA production 💬	[1] ITGA4 💬 Intestinal immune network for IgA production × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Intestinal immune network for IgA production × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 29. Intestinal immune network for IgA production × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
30	JAK-STAT signaling pathway 💬	[1] CSF3R 💬 JAK-STAT signaling pathway × Name Full Name CSF3R colony stimulating factor 3 receptor	Filgrastim 💬 JAK-STAT signaling pathway × Name Other Names Filgrastim Filgrastim (USP/INN) Filgrastim (genetical recombination) (JP18) Filgrastim (genetical recombination) [Filgrastim biosimilar 1] (JAN) Tbo-filgrastim Filgrastim (genetical recombination) [Filgrastim biosimilar 2] (JAN) Filgrastim (genetical recombination) [Filgrastim biosimilar 3] (JAN) Filgrastim-sndz Filgrastim-aafi Neupogen (TN) Nivestym (TN) Grastofil (TN) Zarxio (TN) GRANIX NEUPOGEN NIVESTYM NYPOZI RELEUKO ZARXIO	Filgrastim	[29]  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 30. JAK-STAT signaling pathway × Disease ID Name  2  Amyotrophic lateral sclerosis;ALS;  6  Parkinson disease;Disease Parkinson's; 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 26 HTLV-1-associated myelopathy;Tropical spastic paraparesis;HTLV-1;HTLV-I;HAM; 28 Systemic amyloidosis;Immunoglobulin light chain amyloidosis;Amyloid light-chain amyloidosis;AL amyloidosis;Immunoglobulin light chain amyloidosis;Immunoglobulin-related amyloidosis;Amyloid heavy-chain amyloidosis;Amyloid heavy-chain amyloidosis;AH amyloidosis;Systemic wild-type transthyretin amyloidosis;Senile systemic amyloidosis;SSA;Hereditary transthyretin amyloidosis;Familial amyloidosis;Familial amyloid polyneuropathy;FAP;Hereditary systemic amyloidosis; 34 Neurofibromatosis;Neurofibromatosis type 1;NF1;Recklinghausen disease;Neurofibromatosis type 2;NF2; 35 Pemphigus; 38 Stevens-Johnson syndrome;SJS;Mucocutaneous ocular syndrome; 40 Takayasu arteritis;Aortitis syndrome;Pulseless disease;Aortitis syndrome; 41 Giant cell arteritis;Temporal arteritis; 42 Polyarteritis nodosa;PAN; 45 Eosinophilic granulomatosis with Polyangiitis;EGPA;Eosinophilic multiple vasculitis granulomatous disease;Allergic granulomatous angiitis;AGA;Churg-Strauss syndrome;CSS; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 47 Buerger disease;Thromboangiitis obliterans; 49 Systemic lupus erythematosus;SLE; 51 Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc; 60 Aplastic anemia; 62 Paroxysmal nocturnal hemoglobinuria;PNH; 65 Primary immunodeficiency;X-linked severe combined immunodeficiency;X-SCID;Reticular dysgenesis;Adenosine deaminase deficiency;Omenn syndrome;Purine nucleoside phosphorylase deficiency;CD8 deficiency;ZAP-70 deficiency;MHC class I deficiency;MHC class II deficiency;Other combined immunodeficiencies;Wiskott-Aldrich syndrome;WAS;Ataxia telangiectasia;Nijmegen breakage syndrome;Bloom syndrome;Immunodeficiency, centromere region instability, facial anomalies syndrome;ICF syndrome;PMS2 deficiency;Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome;RIDDLE syndrome;Schimke syndrome;Netherton syndrome;Thymic hypoplasia;DiGeorge syndrome;22q11.2 deletion syndrome;Hyper-IgE syndrome;Hepatic venoocclusive immunodeficiency;Immunodeficiency with central hepatic vein atresia;Dyskeratosis congenita;X-linked agammaglobulinaemia;Common variable immunodeficiency;Hyper-IgM syndrome;Isolated IgG subclass deficiency;Selective IgA deficiency;Specific antibody production deficiency;Infant transient hypogammaglobulinemia;Other predominantly antibody deficiencies;Chédiak-Higashi syndrome;Chediak-Higashi syndrome;X-linked lymphoproliferative syndrome;SAP deficiency;SH2D1A/SLAM-associated protein deficiency;XIAP deficiency;X-linked inhibitor of apoptosis deficiency;Autoimmune lymphoproliferative syndrome;ALPS;Other diseases of immune dysregulation;Familial hemophagocytic syndrome;FHPS;Familial hemophagocytic lymphohistiocytosis;FHL;Perforin deficiency;Munc13-4 deficiency;Syntaxin 11 deficiency;Munc18-2 deficiency;Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;APECED;Autoimmune polyglandular syndrome;APS;Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome;IPEX syndrome;CD25 deficiency;ITCH deficiency;Severe congenital neutropenia;Cyclic neutropenia;Other congenital defects of neutrophil function;p14 deficiency;Glycogen storage disease type Ib;Leukocyte adhesion deficiency;Shwachman-Diamond syndrome;Chronic granulomatous disease;Myeloperoxidase deficiency;Mendelian susceptibility to mycobacterial disease;MSMD;Other congenital defects of phagocyte function;Anhidrotic ectodermal dysplasia with immunodeficiency;EDA-ID;Interleukin-1 receptor-associated kinase-4 deficiency;IRAK4 deficiency;MyD88 deficiency;Chronic mucocutaneous candidiasis;Other defects in innate immunity;Warts, hypogammaglobulinemia, infections, myelokathexis syndrome;WHIM syndrome;Congenital complement deficiency;C1q deficiency;C1r deficiency;C1s deficiency;C2 deficiency;C3 deficiency;C4 deficiency;C5 deficiency;C6 deficiency;C7 deficiency;C8 deficiency;C9 deficiency;Hereditary angioedema;C1 inhibitor deficiency;Inherited deficiency of complement system;Factor D deficiency;Factor I deficiency;Factor H deficiency;Properdin deficiency;MASP1 deficiency;MASP2 deficiency;3MC syndrome;Immunodeficiency associated with FCN3 mutation;FCN3; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD; 113 Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy; 164 Oculocutaneous albinism;Hermansky-Pudlak syndrome;HPS;Chediak-Higashi syndrome;Chédiak-Higashi syndrome;CHS;Griscelli syndrome; 256 Muscle glycogenosis;Muscular glycogenosis;Muscle glycogen storage disease;Muscular glycogen storage disease;Glycogen storage disease type 0;GSD0;Glycogen synthase deficiency;Glycogen storage disease type II;GSDII;Pompe disease;Alpha-1,4-glucosidase acid deficiency;Glycogen storage disease type III;GSDIII;Cori disease;Forbes disease;Glycogen debranching enzyme deficiency;Glycogen storage disease type IV;GSDIV;Andersen disease;Glycogen-branching enzyme deficiency;GBED;Glycogen storage disease type V;GSDV;McArdle disease;Muscle phosphorylase deficiency;Muscular phosphorylase deficiency;Glycogen storage disease type VII;GSDVII;Tarui disease;Phosphofructokinase deficiency;PFK deficiency;Glycogen storage disease type IXd;GSDIXd;Phosphorylase kinase deficiency;Phosphoglycerate kinase deficiency;PGK deficiency;Glycogen storage disease type X;GSDX;Phosphoglycerate mutase deficiency;Glycogen storage diseass type XI;GSDXI;Kanno disease;Lactate dehydrogenase deficiency;Glycogen storage diseass type XII;GSDXII;Aldolase A deficiency;Glycogen storage diseass type XIII;GSDXIII;Beta-enolase deficiency;Glycogen storage diseass type XIV;GSDXIV;Phosphoglucomutase deficiency;Glycogen storage diseass type XV;GSDXV;Glycogenin 1 deficiency; 283 Acquired pure red cell aplasia;Pure red cell aplasia; 284 Diamond-Blackfan anemia; 285 Fanconi anemia; 296 Biliary atresia; 331 Idiopathic multicentric castleman disease;iMCD;Castleman disease;
31	JAK-STAT signaling pathway 💬	[2] IFNAR1, IFNAR2 💬 JAK-STAT signaling pathway × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 JAK-STAT signaling pathway × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 31. JAK-STAT signaling pathway × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
32	JAK-STAT signaling pathway 💬	[2] IFNAR1, IFNAR2 💬 JAK-STAT signaling pathway × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 JAK-STAT signaling pathway × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 32. JAK-STAT signaling pathway × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
33	Kaposi sarcoma-associated herpesvirus infection 💬	[2] IFNAR1, IFNAR2 💬 Kaposi sarcoma-associated herpesvirus infection × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Kaposi sarcoma-associated herpesvirus infection × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 33. Kaposi sarcoma-associated herpesvirus infection × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
34	Kaposi sarcoma-associated herpesvirus infection 💬	[2] IFNAR1, IFNAR2 💬 Kaposi sarcoma-associated herpesvirus infection × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Kaposi sarcoma-associated herpesvirus infection × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 34. Kaposi sarcoma-associated herpesvirus infection × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
35	Leishmaniasis 💬	[1] ITGA4 💬 Leishmaniasis × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Leishmaniasis × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 35. Leishmaniasis × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
36	Leukocyte transendothelial migration 💬	[1] ITGA4 💬 Leukocyte transendothelial migration × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Leukocyte transendothelial migration × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 36. Leukocyte transendothelial migration × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
37	Measles 💬	[2] IFNAR1, IFNAR2 💬 Measles × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Measles × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 37. Measles × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
38	Measles 💬	[2] IFNAR1, IFNAR2 💬 Measles × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Measles × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 38. Measles × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
39	Natural killer cell mediated cytotoxicity 💬	[2] IFNAR1, IFNAR2 💬 Natural killer cell mediated cytotoxicity × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Natural killer cell mediated cytotoxicity × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 39. Natural killer cell mediated cytotoxicity × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
40	Natural killer cell mediated cytotoxicity 💬	[2] IFNAR1, IFNAR2 💬 Natural killer cell mediated cytotoxicity × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Natural killer cell mediated cytotoxicity × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 40. Natural killer cell mediated cytotoxicity × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
41	Necroptosis 💬	[2] IFNAR1, IFNAR2 💬 Necroptosis × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Necroptosis × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 41. Necroptosis × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
42	Necroptosis 💬	[2] IFNAR1, IFNAR2 💬 Necroptosis × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Necroptosis × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 42. Necroptosis × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
43	Neuroactive ligand-receptor interaction 💬	[1] NR3C1 💬 Neuroactive ligand-receptor interaction × Name Full Name NR3C1 nuclear receptor subfamily 3 group C member 1	Methylprednisolone 💬 Neuroactive ligand-receptor interaction × Name Other Names Methylprednisolone Methylprednisolone (JP18/USP/INN) Medrol (TN) MEDROL METHYLPREDNISOLONE	Methylprednisolone	[48]  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 127, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 💬 43. Neuroactive ligand-receptor interaction × Disease ID Name  2  Amyotrophic lateral sclerosis;ALS;  6  Parkinson disease;Disease Parkinson's; 11 Myasthenia gravis;MG; 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 14 Chronic inflammatory demyelinating polyneuropathy;Chronic inflammatory demyelinating poly (radiculo) neuropathy;CIDP;Multifocal motor neuropathy; 18 Spinocerebellar degeneration;SCD;:Spinocerebellar ataxia;SCA;Machado-Joseph disease;MJD;Dentatorubural pallidoluysian atrophy;Dentatorubropallidoluysial atrophy;DRPLA;Naito-Koyanagi disease;Early-onset ataxia with ocular motor ataxia and hypoalbuminemia;EAOH;Neu:Ataxia with vitamin E deficiency;AVED;Aprataxin deficiency;APTX deficiency;Friedreich ataxia;FRDA;Senataxin deficiency;SETX deficiency;Autosomal recessive spastic ataxia of Charlevoix-Saguenay;Spastic ataxia; 19 Lysosomal storage disease;Lysosomal disease;Gaucher disease;Niemann-Pick disease type A/B;Niemann-Pick type A;NPD-A;NPA;Niemann-Pick type B;NPD-B;NPB;Acid sphingomyelinase deficiency;ASMD;Niemann-Pick disease type C;Niemann-Pick type C;NPD-C;NPC;GM1-gangliosidosis;GM1-gangliosidoses;GM2-gangliosidosis;GM2-gangliosidoses;Tay-Sachs disease;Sandhoff disease;Krabbe disease;Metachromatic leukodystrophy;MLD;Multiple-sulfatase deficiency;Farber disease;Mucopolysaccharidosis type I;Mucopolysaccharidosis I;MPS I;Hurler syndrome;Hurler-Scheie syndrome;Scheie syndrome;Mucopolysaccharidosis type II;Mucopolysaccharidosis II;MPS II;Hunter syndrome;Mucopolysaccharidosis type III;Mucopolysaccharidosis III;MPS III;Sanfilippo syndrome;Mucopolysaccharidosis type IV;Mucopolysaccharidosis IV;MPS IV;MPS IVA;Morquio syndrome;Morquio A syndrome;Mucopolysaccharidosis type VI;Mucopolysaccharidosis VI;MPS VI;Maroteaux-Lamy syndrome;Mucopolysaccharidosis type VII;Mucopolysaccharidosis VII;MPS VII;Sly syndrome;Mucopolysaccharidosis type IX;Mucopolysaccharidosis IX;MPS IX;Hyaluronidase deficiency;Sialidosis;Galactosialidosis;Mucolipidosis II;Mucolipidosis type II;I-cell disease;Mucolipidosis III;Mucolipidosis type III;Alpha-Mannosidosis;Alpha-Mannosidase Deficiency;Beta-Mannosidosis;Beta-Mannosidase Deficiency;Fucosidosis;Aspartylglucosaminuria;Schindler disease;Kanzaki disease;Pompe disease;Acid lipase deficiency;Wolman disease;Cholesterol ester storage disease;Danon disease;Free sialic acid storage disease;Infantile sialic acid storage disease;ISSD;Salla disease;Ceroid lipofuscinosis;Fabry disease;Cystinosis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 26 HTLV-1-associated myelopathy;Tropical spastic paraparesis;HTLV-1;HTLV-I;HAM; 35 Pemphigus; 38 Stevens-Johnson syndrome;SJS;Mucocutaneous ocular syndrome; 39 Toxic epidermal necrolysis;Toxic epidermal necrosis;TEN; 40 Takayasu arteritis;Aortitis syndrome;Pulseless disease;Aortitis syndrome; 41 Giant cell arteritis;Temporal arteritis; 42 Polyarteritis nodosa;PAN; 43 Microscopic polyangiitis;MPA; 45 Eosinophilic granulomatosis with Polyangiitis;EGPA;Eosinophilic multiple vasculitis granulomatous disease;Allergic granulomatous angiitis;AGA;Churg-Strauss syndrome;CSS; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 49 Systemic lupus erythematosus;SLE; 50 Dermatomyositis;Polymyositis; 51 Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc; 60 Aplastic anemia; 62 Paroxysmal nocturnal hemoglobinuria;PNH; 63 Idiopathic thrombocytopenic purpura;Primary immune thrombocytopenia;Immune thrombocytopenic purpura; 64 Thrombotic thrombocytopenic purpura;TTP;Upshaw-Schulman syndrome;USS; 65 Primary immunodeficiency;X-linked severe combined immunodeficiency;X-SCID;Reticular dysgenesis;Adenosine deaminase deficiency;Omenn syndrome;Purine nucleoside phosphorylase deficiency;CD8 deficiency;ZAP-70 deficiency;MHC class I deficiency;MHC class II deficiency;Other combined immunodeficiencies;Wiskott-Aldrich syndrome;WAS;Ataxia telangiectasia;Nijmegen breakage syndrome;Bloom syndrome;Immunodeficiency, centromere region instability, facial anomalies syndrome;ICF syndrome;PMS2 deficiency;Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome;RIDDLE syndrome;Schimke syndrome;Netherton syndrome;Thymic hypoplasia;DiGeorge syndrome;22q11.2 deletion syndrome;Hyper-IgE syndrome;Hepatic venoocclusive immunodeficiency;Immunodeficiency with central hepatic vein atresia;Dyskeratosis congenita;X-linked agammaglobulinaemia;Common variable immunodeficiency;Hyper-IgM syndrome;Isolated IgG subclass deficiency;Selective IgA deficiency;Specific antibody production deficiency;Infant transient hypogammaglobulinemia;Other predominantly antibody deficiencies;Chédiak-Higashi syndrome;Chediak-Higashi syndrome;X-linked lymphoproliferative syndrome;SAP deficiency;SH2D1A/SLAM-associated protein deficiency;XIAP deficiency;X-linked inhibitor of apoptosis deficiency;Autoimmune lymphoproliferative syndrome;ALPS;Other diseases of immune dysregulation;Familial hemophagocytic syndrome;FHPS;Familial hemophagocytic lymphohistiocytosis;FHL;Perforin deficiency;Munc13-4 deficiency;Syntaxin 11 deficiency;Munc18-2 deficiency;Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;APECED;Autoimmune polyglandular syndrome;APS;Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome;IPEX syndrome;CD25 deficiency;ITCH deficiency;Severe congenital neutropenia;Cyclic neutropenia;Other congenital defects of neutrophil function;p14 deficiency;Glycogen storage disease type Ib;Leukocyte adhesion deficiency;Shwachman-Diamond syndrome;Chronic granulomatous disease;Myeloperoxidase deficiency;Mendelian susceptibility to mycobacterial disease;MSMD;Other congenital defects of phagocyte function;Anhidrotic ectodermal dysplasia with immunodeficiency;EDA-ID;Interleukin-1 receptor-associated kinase-4 deficiency;IRAK4 deficiency;MyD88 deficiency;Chronic mucocutaneous candidiasis;Other defects in innate immunity;Warts, hypogammaglobulinemia, infections, myelokathexis syndrome;WHIM syndrome;Congenital complement deficiency;C1q deficiency;C1r deficiency;C1s deficiency;C2 deficiency;C3 deficiency;C4 deficiency;C5 deficiency;C6 deficiency;C7 deficiency;C8 deficiency;C9 deficiency;Hereditary angioedema;C1 inhibitor deficiency;Inherited deficiency of complement system;Factor D deficiency;Factor I deficiency;Factor H deficiency;Properdin deficiency;MASP1 deficiency;MASP2 deficiency;3MC syndrome;Immunodeficiency associated with FCN3 mutation;FCN3; 66 IgA nephropathy;IgA nephritis;Berger disease;IgA-IgG nephropathy; 83 Addison disease;Primary chronic adrenocortical insufficiency; 84 Sarcoidosis; 85 Idiopathic interstitial pneumonia;IIPs;Idiopathic pulmonary fibrosis;IPF;Idiopathic non-specific interstitial pneumonia;Idiopathic NSIP;Respiratory bronchiolitis - associated interstitial lung disease;RB-ILD;Desquamative interstitial pneumonia;DIP;Cryptogenic organizing pneumonia;COP;Acute interstitial pneumonia;AIP;Idiopathic lymphocytic interstitial pneumonia;Idiopathic LIP;Idiopathic PPFE; 86 Pulmonary arterial hypertension;PAH; 93 Primary biliary cholangitis;Primary biliary cirrhosis;PBC; 95 Autoimmune hepatitis; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD; 97 Ulcerative colitis;UC;Inflammatory bowel disease;IBD; 127 Frontotemporal lobar degeneration;Frontotemporal dementia, behavioral abnormal type;Frontotemporal dementia;Semantic dementia; 162 Pemphigoid; 164 Oculocutaneous albinism;Hermansky-Pudlak syndrome;HPS;Chediak-Higashi syndrome;Chédiak-Higashi syndrome;CHS;Griscelli syndrome; 211 Hypoplastic left heart syndrome;HLHS; 220 Rapidly progressive glomerulonephritis; 222 Primary nephrotic syndrome;Minimal change nephrotic syndrome;MCNS;Membranous nephropathy;Focal segmental glomerulosclerosis;FSGS;Membranoproliferative glomerulonephritis;MPGN; 224 Purpura nephritis;Henoch-Schönlein purpura nephritis;HSPN; 271 Ankylosing spondylitis;Spondylarthritis ankylopoietica; 283 Acquired pure red cell aplasia;Pure red cell aplasia; 284 Diamond-Blackfan anemia; 285 Fanconi anemia; 296 Biliary atresia; 300 IgG4-related disease;IgG4-related disease;Autoimmune pancreatitis;IgG4-related sclerosing cholangitis;IgG4-related lacrimal gland, orbital, and salivary gland lesions;IgG4-related kidney disease;
44	Neuroactive ligand-receptor interaction 💬	[1] NR3C1 💬 Neuroactive ligand-receptor interaction × Name Full Name NR3C1 nuclear receptor subfamily 3 group C member 1	Methylprednisolone acetate 💬 Neuroactive ligand-receptor interaction × Name Other Names Methylprednisolone acetate Methylprednisolone acetate (JAN/USP) Depo-medrol (TN) DEPO-MEDROL METHYLPREDNISOLONE ACETATE	Methylprednisolone	[48]  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 127, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 💬 43. Neuroactive ligand-receptor interaction × Disease ID Name  2  Amyotrophic lateral sclerosis;ALS;  6  Parkinson disease;Disease Parkinson's; 11 Myasthenia gravis;MG; 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 14 Chronic inflammatory demyelinating polyneuropathy;Chronic inflammatory demyelinating poly (radiculo) neuropathy;CIDP;Multifocal motor neuropathy; 18 Spinocerebellar degeneration;SCD;:Spinocerebellar ataxia;SCA;Machado-Joseph disease;MJD;Dentatorubural pallidoluysian atrophy;Dentatorubropallidoluysial atrophy;DRPLA;Naito-Koyanagi disease;Early-onset ataxia with ocular motor ataxia and hypoalbuminemia;EAOH;Neu:Ataxia with vitamin E deficiency;AVED;Aprataxin deficiency;APTX deficiency;Friedreich ataxia;FRDA;Senataxin deficiency;SETX deficiency;Autosomal recessive spastic ataxia of Charlevoix-Saguenay;Spastic ataxia; 19 Lysosomal storage disease;Lysosomal disease;Gaucher disease;Niemann-Pick disease type A/B;Niemann-Pick type A;NPD-A;NPA;Niemann-Pick type B;NPD-B;NPB;Acid sphingomyelinase deficiency;ASMD;Niemann-Pick disease type C;Niemann-Pick type C;NPD-C;NPC;GM1-gangliosidosis;GM1-gangliosidoses;GM2-gangliosidosis;GM2-gangliosidoses;Tay-Sachs disease;Sandhoff disease;Krabbe disease;Metachromatic leukodystrophy;MLD;Multiple-sulfatase deficiency;Farber disease;Mucopolysaccharidosis type I;Mucopolysaccharidosis I;MPS I;Hurler syndrome;Hurler-Scheie syndrome;Scheie syndrome;Mucopolysaccharidosis type II;Mucopolysaccharidosis II;MPS II;Hunter syndrome;Mucopolysaccharidosis type III;Mucopolysaccharidosis III;MPS III;Sanfilippo syndrome;Mucopolysaccharidosis type IV;Mucopolysaccharidosis IV;MPS IV;MPS IVA;Morquio syndrome;Morquio A syndrome;Mucopolysaccharidosis type VI;Mucopolysaccharidosis VI;MPS VI;Maroteaux-Lamy syndrome;Mucopolysaccharidosis type VII;Mucopolysaccharidosis VII;MPS VII;Sly syndrome;Mucopolysaccharidosis type IX;Mucopolysaccharidosis IX;MPS IX;Hyaluronidase deficiency;Sialidosis;Galactosialidosis;Mucolipidosis II;Mucolipidosis type II;I-cell disease;Mucolipidosis III;Mucolipidosis type III;Alpha-Mannosidosis;Alpha-Mannosidase Deficiency;Beta-Mannosidosis;Beta-Mannosidase Deficiency;Fucosidosis;Aspartylglucosaminuria;Schindler disease;Kanzaki disease;Pompe disease;Acid lipase deficiency;Wolman disease;Cholesterol ester storage disease;Danon disease;Free sialic acid storage disease;Infantile sialic acid storage disease;ISSD;Salla disease;Ceroid lipofuscinosis;Fabry disease;Cystinosis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 26 HTLV-1-associated myelopathy;Tropical spastic paraparesis;HTLV-1;HTLV-I;HAM; 35 Pemphigus; 38 Stevens-Johnson syndrome;SJS;Mucocutaneous ocular syndrome; 39 Toxic epidermal necrolysis;Toxic epidermal necrosis;TEN; 40 Takayasu arteritis;Aortitis syndrome;Pulseless disease;Aortitis syndrome; 41 Giant cell arteritis;Temporal arteritis; 42 Polyarteritis nodosa;PAN; 43 Microscopic polyangiitis;MPA; 45 Eosinophilic granulomatosis with Polyangiitis;EGPA;Eosinophilic multiple vasculitis granulomatous disease;Allergic granulomatous angiitis;AGA;Churg-Strauss syndrome;CSS; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 49 Systemic lupus erythematosus;SLE; 50 Dermatomyositis;Polymyositis; 51 Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc; 60 Aplastic anemia; 62 Paroxysmal nocturnal hemoglobinuria;PNH; 63 Idiopathic thrombocytopenic purpura;Primary immune thrombocytopenia;Immune thrombocytopenic purpura; 64 Thrombotic thrombocytopenic purpura;TTP;Upshaw-Schulman syndrome;USS; 65 Primary immunodeficiency;X-linked severe combined immunodeficiency;X-SCID;Reticular dysgenesis;Adenosine deaminase deficiency;Omenn syndrome;Purine nucleoside phosphorylase deficiency;CD8 deficiency;ZAP-70 deficiency;MHC class I deficiency;MHC class II deficiency;Other combined immunodeficiencies;Wiskott-Aldrich syndrome;WAS;Ataxia telangiectasia;Nijmegen breakage syndrome;Bloom syndrome;Immunodeficiency, centromere region instability, facial anomalies syndrome;ICF syndrome;PMS2 deficiency;Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome;RIDDLE syndrome;Schimke syndrome;Netherton syndrome;Thymic hypoplasia;DiGeorge syndrome;22q11.2 deletion syndrome;Hyper-IgE syndrome;Hepatic venoocclusive immunodeficiency;Immunodeficiency with central hepatic vein atresia;Dyskeratosis congenita;X-linked agammaglobulinaemia;Common variable immunodeficiency;Hyper-IgM syndrome;Isolated IgG subclass deficiency;Selective IgA deficiency;Specific antibody production deficiency;Infant transient hypogammaglobulinemia;Other predominantly antibody deficiencies;Chédiak-Higashi syndrome;Chediak-Higashi syndrome;X-linked lymphoproliferative syndrome;SAP deficiency;SH2D1A/SLAM-associated protein deficiency;XIAP deficiency;X-linked inhibitor of apoptosis deficiency;Autoimmune lymphoproliferative syndrome;ALPS;Other diseases of immune dysregulation;Familial hemophagocytic syndrome;FHPS;Familial hemophagocytic lymphohistiocytosis;FHL;Perforin deficiency;Munc13-4 deficiency;Syntaxin 11 deficiency;Munc18-2 deficiency;Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;APECED;Autoimmune polyglandular syndrome;APS;Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome;IPEX syndrome;CD25 deficiency;ITCH deficiency;Severe congenital neutropenia;Cyclic neutropenia;Other congenital defects of neutrophil function;p14 deficiency;Glycogen storage disease type Ib;Leukocyte adhesion deficiency;Shwachman-Diamond syndrome;Chronic granulomatous disease;Myeloperoxidase deficiency;Mendelian susceptibility to mycobacterial disease;MSMD;Other congenital defects of phagocyte function;Anhidrotic ectodermal dysplasia with immunodeficiency;EDA-ID;Interleukin-1 receptor-associated kinase-4 deficiency;IRAK4 deficiency;MyD88 deficiency;Chronic mucocutaneous candidiasis;Other defects in innate immunity;Warts, hypogammaglobulinemia, infections, myelokathexis syndrome;WHIM syndrome;Congenital complement deficiency;C1q deficiency;C1r deficiency;C1s deficiency;C2 deficiency;C3 deficiency;C4 deficiency;C5 deficiency;C6 deficiency;C7 deficiency;C8 deficiency;C9 deficiency;Hereditary angioedema;C1 inhibitor deficiency;Inherited deficiency of complement system;Factor D deficiency;Factor I deficiency;Factor H deficiency;Properdin deficiency;MASP1 deficiency;MASP2 deficiency;3MC syndrome;Immunodeficiency associated with FCN3 mutation;FCN3; 66 IgA nephropathy;IgA nephritis;Berger disease;IgA-IgG nephropathy; 83 Addison disease;Primary chronic adrenocortical insufficiency; 84 Sarcoidosis; 85 Idiopathic interstitial pneumonia;IIPs;Idiopathic pulmonary fibrosis;IPF;Idiopathic non-specific interstitial pneumonia;Idiopathic NSIP;Respiratory bronchiolitis - associated interstitial lung disease;RB-ILD;Desquamative interstitial pneumonia;DIP;Cryptogenic organizing pneumonia;COP;Acute interstitial pneumonia;AIP;Idiopathic lymphocytic interstitial pneumonia;Idiopathic LIP;Idiopathic PPFE; 86 Pulmonary arterial hypertension;PAH; 93 Primary biliary cholangitis;Primary biliary cirrhosis;PBC; 95 Autoimmune hepatitis; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD; 97 Ulcerative colitis;UC;Inflammatory bowel disease;IBD; 127 Frontotemporal lobar degeneration;Frontotemporal dementia, behavioral abnormal type;Frontotemporal dementia;Semantic dementia; 162 Pemphigoid; 164 Oculocutaneous albinism;Hermansky-Pudlak syndrome;HPS;Chediak-Higashi syndrome;Chédiak-Higashi syndrome;CHS;Griscelli syndrome; 211 Hypoplastic left heart syndrome;HLHS; 220 Rapidly progressive glomerulonephritis; 222 Primary nephrotic syndrome;Minimal change nephrotic syndrome;MCNS;Membranous nephropathy;Focal segmental glomerulosclerosis;FSGS;Membranoproliferative glomerulonephritis;MPGN; 224 Purpura nephritis;Henoch-Schönlein purpura nephritis;HSPN; 271 Ankylosing spondylitis;Spondylarthritis ankylopoietica; 283 Acquired pure red cell aplasia;Pure red cell aplasia; 284 Diamond-Blackfan anemia; 285 Fanconi anemia; 296 Biliary atresia; 300 IgG4-related disease;IgG4-related disease;Autoimmune pancreatitis;IgG4-related sclerosing cholangitis;IgG4-related lacrimal gland, orbital, and salivary gland lesions;IgG4-related kidney disease;
45	Neuroactive ligand-receptor interaction 💬	[1] NR3C1 💬 Neuroactive ligand-receptor interaction × Name Full Name NR3C1 nuclear receptor subfamily 3 group C member 1	Prednisolone 💬 Neuroactive ligand-receptor interaction × Name Other Names Prednisolone Prednisolone (JP18/USP/INN) Delta-cortef (TN)	Prednisolone	[41]  3 , 11, 13, 14, 18, 25, 26, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 54, 56, 60, 61, 63, 64, 66, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 251, 269, 271, 296, 299, 300 💬 45. Neuroactive ligand-receptor interaction × Disease ID Name  3  Spinal muscular atrophy;SMA;Myelopathic muscular atrophy;Werdnig-Hoffman disease;Dubowitz disease;Kugelberg-Welander disease; 11 Myasthenia gravis;MG; 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 14 Chronic inflammatory demyelinating polyneuropathy;Chronic inflammatory demyelinating poly (radiculo) neuropathy;CIDP;Multifocal motor neuropathy; 18 Spinocerebellar degeneration;SCD;:Spinocerebellar ataxia;SCA;Machado-Joseph disease;MJD;Dentatorubural pallidoluysian atrophy;Dentatorubropallidoluysial atrophy;DRPLA;Naito-Koyanagi disease;Early-onset ataxia with ocular motor ataxia and hypoalbuminemia;EAOH;Neu:Ataxia with vitamin E deficiency;AVED;Aprataxin deficiency;APTX deficiency;Friedreich ataxia;FRDA;Senataxin deficiency;SETX deficiency;Autosomal recessive spastic ataxia of Charlevoix-Saguenay;Spastic ataxia; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 26 HTLV-1-associated myelopathy;Tropical spastic paraparesis;HTLV-1;HTLV-I;HAM; 38 Stevens-Johnson syndrome;SJS;Mucocutaneous ocular syndrome; 39 Toxic epidermal necrolysis;Toxic epidermal necrosis;TEN; 40 Takayasu arteritis;Aortitis syndrome;Pulseless disease;Aortitis syndrome; 41 Giant cell arteritis;Temporal arteritis; 43 Microscopic polyangiitis;MPA; 44 Wegener granulomatosis;Multiple vasculitis granulomatous disease;Granulomatosis with polyangiitis; 45 Eosinophilic granulomatosis with Polyangiitis;EGPA;Eosinophilic multiple vasculitis granulomatous disease;Allergic granulomatous angiitis;AGA;Churg-Strauss syndrome;CSS; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 49 Systemic lupus erythematosus;SLE; 50 Dermatomyositis;Polymyositis; 51 Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc; 54 Adult still disease;Adult-onset Still's disease; 56 Behcet disease;Behçet disease;BD; 60 Aplastic anemia; 61 Autoimmune hemolytic anemia;AIHA;Cold agglutinin disease;CAD;Paroxysmal cold hemoglobinuria;Evans syndrome; 63 Idiopathic thrombocytopenic purpura;Primary immune thrombocytopenia;Immune thrombocytopenic purpura; 64 Thrombotic thrombocytopenic purpura;TTP;Upshaw-Schulman syndrome;USS; 66 IgA nephropathy;IgA nephritis;Berger disease;IgA-IgG nephropathy; 81 Congenital adrenal hyperplasia;CAH;Congenital adrenal enzyme deficiency;Congenial adrenal cortex enzyme deficiency;Congenital Lipoid Adrenal Hyperplasia;3β-Hydroxysteroid Dehydrogenase Deficiency;21-Hydroxylase deficiency;21-OHD;11β-Hydroxylase deficiency;17α-Hydroxylase deficiency;P450 oxidoreductase deficiency; 84 Sarcoidosis; 85 Idiopathic interstitial pneumonia;IIPs;Idiopathic pulmonary fibrosis;IPF;Idiopathic non-specific interstitial pneumonia;Idiopathic NSIP;Respiratory bronchiolitis - associated interstitial lung disease;RB-ILD;Desquamative interstitial pneumonia;DIP;Cryptogenic organizing pneumonia;COP;Acute interstitial pneumonia;AIP;Idiopathic lymphocytic interstitial pneumonia;Idiopathic LIP;Idiopathic PPFE; 95 Autoimmune hepatitis; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD; 97 Ulcerative colitis;UC;Inflammatory bowel disease;IBD; 113 Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy; 145 West syndrome;Infantile spasm;Infantile spasms;Infantile spasms syndrome;Infantile epileptic spasms;Infantile epileptic spasms syndrome; 162 Pemphigoid; 222 Primary nephrotic syndrome;Minimal change nephrotic syndrome;MCNS;Membranous nephropathy;Focal segmental glomerulosclerosis;FSGS;Membranoproliferative glomerulonephritis;MPGN; 251 Urea cycle disorder;N-acetylglutamate synthase deficiency;NAGS deficiency;Carbamoyl phosphate synthetase I deficiency;CPS1 deficiency;Ornithine transcarbamylase deficiency;OTC deficiency;Classic citrullinemia;Citrullinemia type I;Argininosuccinic aciduria;Argininemia;Hiperornitinemia-hiperamonemia-homocitrulinuria syndrome;HHH syndrome; 269 Pyogenic arthritis;Pyoderma gangrenosum;Acne syndrome;PAPA syndrome; 271 Ankylosing spondylitis;Spondylarthritis ankylopoietica; 296 Biliary atresia; 299 Cystic fibrosis;CF; 300 IgG4-related disease;IgG4-related disease;Autoimmune pancreatitis;IgG4-related sclerosing cholangitis;IgG4-related lacrimal gland, orbital, and salivary gland lesions;IgG4-related kidney disease;
46	NOD-like receptor signaling pathway 💬	[2] IFNAR1, IFNAR2 💬 NOD-like receptor signaling pathway × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 NOD-like receptor signaling pathway × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 46. NOD-like receptor signaling pathway × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
47	NOD-like receptor signaling pathway 💬	[2] IFNAR1, IFNAR2 💬 NOD-like receptor signaling pathway × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 NOD-like receptor signaling pathway × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 47. NOD-like receptor signaling pathway × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
48	Osteoclast differentiation 💬	[2] IFNAR1, IFNAR2 💬 Osteoclast differentiation × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Osteoclast differentiation × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 48. Osteoclast differentiation × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
49	Osteoclast differentiation 💬	[2] IFNAR1, IFNAR2 💬 Osteoclast differentiation × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Osteoclast differentiation × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 49. Osteoclast differentiation × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
50	Pathways in cancer 💬	[1] CSF3R 💬 Pathways in cancer × Name Full Name CSF3R colony stimulating factor 3 receptor	Filgrastim 💬 Pathways in cancer × Name Other Names Filgrastim Filgrastim (USP/INN) Filgrastim (genetical recombination) (JP18) Filgrastim (genetical recombination) [Filgrastim biosimilar 1] (JAN) Tbo-filgrastim Filgrastim (genetical recombination) [Filgrastim biosimilar 2] (JAN) Filgrastim (genetical recombination) [Filgrastim biosimilar 3] (JAN) Filgrastim-sndz Filgrastim-aafi Neupogen (TN) Nivestym (TN) Grastofil (TN) Zarxio (TN) GRANIX NEUPOGEN NIVESTYM NYPOZI RELEUKO ZARXIO	Filgrastim	[29]  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 50. Pathways in cancer × Disease ID Name  2  Amyotrophic lateral sclerosis;ALS;  6  Parkinson disease;Disease Parkinson's; 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 26 HTLV-1-associated myelopathy;Tropical spastic paraparesis;HTLV-1;HTLV-I;HAM; 28 Systemic amyloidosis;Immunoglobulin light chain amyloidosis;Amyloid light-chain amyloidosis;AL amyloidosis;Immunoglobulin light chain amyloidosis;Immunoglobulin-related amyloidosis;Amyloid heavy-chain amyloidosis;Amyloid heavy-chain amyloidosis;AH amyloidosis;Systemic wild-type transthyretin amyloidosis;Senile systemic amyloidosis;SSA;Hereditary transthyretin amyloidosis;Familial amyloidosis;Familial amyloid polyneuropathy;FAP;Hereditary systemic amyloidosis; 34 Neurofibromatosis;Neurofibromatosis type 1;NF1;Recklinghausen disease;Neurofibromatosis type 2;NF2; 35 Pemphigus; 38 Stevens-Johnson syndrome;SJS;Mucocutaneous ocular syndrome; 40 Takayasu arteritis;Aortitis syndrome;Pulseless disease;Aortitis syndrome; 41 Giant cell arteritis;Temporal arteritis; 42 Polyarteritis nodosa;PAN; 45 Eosinophilic granulomatosis with Polyangiitis;EGPA;Eosinophilic multiple vasculitis granulomatous disease;Allergic granulomatous angiitis;AGA;Churg-Strauss syndrome;CSS; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 47 Buerger disease;Thromboangiitis obliterans; 49 Systemic lupus erythematosus;SLE; 51 Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc; 60 Aplastic anemia; 62 Paroxysmal nocturnal hemoglobinuria;PNH; 65 Primary immunodeficiency;X-linked severe combined immunodeficiency;X-SCID;Reticular dysgenesis;Adenosine deaminase deficiency;Omenn syndrome;Purine nucleoside phosphorylase deficiency;CD8 deficiency;ZAP-70 deficiency;MHC class I deficiency;MHC class II deficiency;Other combined immunodeficiencies;Wiskott-Aldrich syndrome;WAS;Ataxia telangiectasia;Nijmegen breakage syndrome;Bloom syndrome;Immunodeficiency, centromere region instability, facial anomalies syndrome;ICF syndrome;PMS2 deficiency;Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome;RIDDLE syndrome;Schimke syndrome;Netherton syndrome;Thymic hypoplasia;DiGeorge syndrome;22q11.2 deletion syndrome;Hyper-IgE syndrome;Hepatic venoocclusive immunodeficiency;Immunodeficiency with central hepatic vein atresia;Dyskeratosis congenita;X-linked agammaglobulinaemia;Common variable immunodeficiency;Hyper-IgM syndrome;Isolated IgG subclass deficiency;Selective IgA deficiency;Specific antibody production deficiency;Infant transient hypogammaglobulinemia;Other predominantly antibody deficiencies;Chédiak-Higashi syndrome;Chediak-Higashi syndrome;X-linked lymphoproliferative syndrome;SAP deficiency;SH2D1A/SLAM-associated protein deficiency;XIAP deficiency;X-linked inhibitor of apoptosis deficiency;Autoimmune lymphoproliferative syndrome;ALPS;Other diseases of immune dysregulation;Familial hemophagocytic syndrome;FHPS;Familial hemophagocytic lymphohistiocytosis;FHL;Perforin deficiency;Munc13-4 deficiency;Syntaxin 11 deficiency;Munc18-2 deficiency;Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;APECED;Autoimmune polyglandular syndrome;APS;Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome;IPEX syndrome;CD25 deficiency;ITCH deficiency;Severe congenital neutropenia;Cyclic neutropenia;Other congenital defects of neutrophil function;p14 deficiency;Glycogen storage disease type Ib;Leukocyte adhesion deficiency;Shwachman-Diamond syndrome;Chronic granulomatous disease;Myeloperoxidase deficiency;Mendelian susceptibility to mycobacterial disease;MSMD;Other congenital defects of phagocyte function;Anhidrotic ectodermal dysplasia with immunodeficiency;EDA-ID;Interleukin-1 receptor-associated kinase-4 deficiency;IRAK4 deficiency;MyD88 deficiency;Chronic mucocutaneous candidiasis;Other defects in innate immunity;Warts, hypogammaglobulinemia, infections, myelokathexis syndrome;WHIM syndrome;Congenital complement deficiency;C1q deficiency;C1r deficiency;C1s deficiency;C2 deficiency;C3 deficiency;C4 deficiency;C5 deficiency;C6 deficiency;C7 deficiency;C8 deficiency;C9 deficiency;Hereditary angioedema;C1 inhibitor deficiency;Inherited deficiency of complement system;Factor D deficiency;Factor I deficiency;Factor H deficiency;Properdin deficiency;MASP1 deficiency;MASP2 deficiency;3MC syndrome;Immunodeficiency associated with FCN3 mutation;FCN3; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD; 113 Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy; 164 Oculocutaneous albinism;Hermansky-Pudlak syndrome;HPS;Chediak-Higashi syndrome;Chédiak-Higashi syndrome;CHS;Griscelli syndrome; 256 Muscle glycogenosis;Muscular glycogenosis;Muscle glycogen storage disease;Muscular glycogen storage disease;Glycogen storage disease type 0;GSD0;Glycogen synthase deficiency;Glycogen storage disease type II;GSDII;Pompe disease;Alpha-1,4-glucosidase acid deficiency;Glycogen storage disease type III;GSDIII;Cori disease;Forbes disease;Glycogen debranching enzyme deficiency;Glycogen storage disease type IV;GSDIV;Andersen disease;Glycogen-branching enzyme deficiency;GBED;Glycogen storage disease type V;GSDV;McArdle disease;Muscle phosphorylase deficiency;Muscular phosphorylase deficiency;Glycogen storage disease type VII;GSDVII;Tarui disease;Phosphofructokinase deficiency;PFK deficiency;Glycogen storage disease type IXd;GSDIXd;Phosphorylase kinase deficiency;Phosphoglycerate kinase deficiency;PGK deficiency;Glycogen storage disease type X;GSDX;Phosphoglycerate mutase deficiency;Glycogen storage diseass type XI;GSDXI;Kanno disease;Lactate dehydrogenase deficiency;Glycogen storage diseass type XII;GSDXII;Aldolase A deficiency;Glycogen storage diseass type XIII;GSDXIII;Beta-enolase deficiency;Glycogen storage diseass type XIV;GSDXIV;Phosphoglucomutase deficiency;Glycogen storage diseass type XV;GSDXV;Glycogenin 1 deficiency; 283 Acquired pure red cell aplasia;Pure red cell aplasia; 284 Diamond-Blackfan anemia; 285 Fanconi anemia; 296 Biliary atresia; 331 Idiopathic multicentric castleman disease;iMCD;Castleman disease;
51	Pathways in cancer 💬	[2] IFNAR1, IFNAR2 💬 Pathways in cancer × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Pathways in cancer × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 51. Pathways in cancer × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
52	Pathways in cancer 💬	[2] IFNAR1, IFNAR2 💬 Pathways in cancer × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Pathways in cancer × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 52. Pathways in cancer × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
53	PD-L1 expression and PD-1 checkpoint pathway in cancer 💬	[1] PDCD1 💬 PD-L1 expression and PD-1 checkpoint pathway in cancer × Name Full Name PDCD1 programmed cell death 1	Pembrolizumab 💬 PD-L1 expression and PD-1 checkpoint pathway in cancer × Name Other Names Pembrolizumab Pembrolizumab (USAN) Pembrolizumab (genetical recombination) (JAN) Keytruda (TN) KEYTRUDA	Pembrolizumab	[2] 25, 285 💬 53. PD-L1 expression and PD-1 checkpoint pathway in cancer × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 285 Fanconi anemia;
54	PI3K-Akt signaling pathway 💬	[1] CSF3R 💬 PI3K-Akt signaling pathway × Name Full Name CSF3R colony stimulating factor 3 receptor	Filgrastim 💬 PI3K-Akt signaling pathway × Name Other Names Filgrastim Filgrastim (USP/INN) Filgrastim (genetical recombination) (JP18) Filgrastim (genetical recombination) [Filgrastim biosimilar 1] (JAN) Tbo-filgrastim Filgrastim (genetical recombination) [Filgrastim biosimilar 2] (JAN) Filgrastim (genetical recombination) [Filgrastim biosimilar 3] (JAN) Filgrastim-sndz Filgrastim-aafi Neupogen (TN) Nivestym (TN) Grastofil (TN) Zarxio (TN) GRANIX NEUPOGEN NIVESTYM NYPOZI RELEUKO ZARXIO	Filgrastim	[29]  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 54. PI3K-Akt signaling pathway × Disease ID Name  2  Amyotrophic lateral sclerosis;ALS;  6  Parkinson disease;Disease Parkinson's; 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 26 HTLV-1-associated myelopathy;Tropical spastic paraparesis;HTLV-1;HTLV-I;HAM; 28 Systemic amyloidosis;Immunoglobulin light chain amyloidosis;Amyloid light-chain amyloidosis;AL amyloidosis;Immunoglobulin light chain amyloidosis;Immunoglobulin-related amyloidosis;Amyloid heavy-chain amyloidosis;Amyloid heavy-chain amyloidosis;AH amyloidosis;Systemic wild-type transthyretin amyloidosis;Senile systemic amyloidosis;SSA;Hereditary transthyretin amyloidosis;Familial amyloidosis;Familial amyloid polyneuropathy;FAP;Hereditary systemic amyloidosis; 34 Neurofibromatosis;Neurofibromatosis type 1;NF1;Recklinghausen disease;Neurofibromatosis type 2;NF2; 35 Pemphigus; 38 Stevens-Johnson syndrome;SJS;Mucocutaneous ocular syndrome; 40 Takayasu arteritis;Aortitis syndrome;Pulseless disease;Aortitis syndrome; 41 Giant cell arteritis;Temporal arteritis; 42 Polyarteritis nodosa;PAN; 45 Eosinophilic granulomatosis with Polyangiitis;EGPA;Eosinophilic multiple vasculitis granulomatous disease;Allergic granulomatous angiitis;AGA;Churg-Strauss syndrome;CSS; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 47 Buerger disease;Thromboangiitis obliterans; 49 Systemic lupus erythematosus;SLE; 51 Scleroderma;Systemic sclerosis;SSc;Diffuse cutaneous SSc;dcSSc;Limited cutaneous SSc;lcSSc; 60 Aplastic anemia; 62 Paroxysmal nocturnal hemoglobinuria;PNH; 65 Primary immunodeficiency;X-linked severe combined immunodeficiency;X-SCID;Reticular dysgenesis;Adenosine deaminase deficiency;Omenn syndrome;Purine nucleoside phosphorylase deficiency;CD8 deficiency;ZAP-70 deficiency;MHC class I deficiency;MHC class II deficiency;Other combined immunodeficiencies;Wiskott-Aldrich syndrome;WAS;Ataxia telangiectasia;Nijmegen breakage syndrome;Bloom syndrome;Immunodeficiency, centromere region instability, facial anomalies syndrome;ICF syndrome;PMS2 deficiency;Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties syndrome;RIDDLE syndrome;Schimke syndrome;Netherton syndrome;Thymic hypoplasia;DiGeorge syndrome;22q11.2 deletion syndrome;Hyper-IgE syndrome;Hepatic venoocclusive immunodeficiency;Immunodeficiency with central hepatic vein atresia;Dyskeratosis congenita;X-linked agammaglobulinaemia;Common variable immunodeficiency;Hyper-IgM syndrome;Isolated IgG subclass deficiency;Selective IgA deficiency;Specific antibody production deficiency;Infant transient hypogammaglobulinemia;Other predominantly antibody deficiencies;Chédiak-Higashi syndrome;Chediak-Higashi syndrome;X-linked lymphoproliferative syndrome;SAP deficiency;SH2D1A/SLAM-associated protein deficiency;XIAP deficiency;X-linked inhibitor of apoptosis deficiency;Autoimmune lymphoproliferative syndrome;ALPS;Other diseases of immune dysregulation;Familial hemophagocytic syndrome;FHPS;Familial hemophagocytic lymphohistiocytosis;FHL;Perforin deficiency;Munc13-4 deficiency;Syntaxin 11 deficiency;Munc18-2 deficiency;Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;APECED;Autoimmune polyglandular syndrome;APS;Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome;IPEX syndrome;CD25 deficiency;ITCH deficiency;Severe congenital neutropenia;Cyclic neutropenia;Other congenital defects of neutrophil function;p14 deficiency;Glycogen storage disease type Ib;Leukocyte adhesion deficiency;Shwachman-Diamond syndrome;Chronic granulomatous disease;Myeloperoxidase deficiency;Mendelian susceptibility to mycobacterial disease;MSMD;Other congenital defects of phagocyte function;Anhidrotic ectodermal dysplasia with immunodeficiency;EDA-ID;Interleukin-1 receptor-associated kinase-4 deficiency;IRAK4 deficiency;MyD88 deficiency;Chronic mucocutaneous candidiasis;Other defects in innate immunity;Warts, hypogammaglobulinemia, infections, myelokathexis syndrome;WHIM syndrome;Congenital complement deficiency;C1q deficiency;C1r deficiency;C1s deficiency;C2 deficiency;C3 deficiency;C4 deficiency;C5 deficiency;C6 deficiency;C7 deficiency;C8 deficiency;C9 deficiency;Hereditary angioedema;C1 inhibitor deficiency;Inherited deficiency of complement system;Factor D deficiency;Factor I deficiency;Factor H deficiency;Properdin deficiency;MASP1 deficiency;MASP2 deficiency;3MC syndrome;Immunodeficiency associated with FCN3 mutation;FCN3; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD; 113 Muscular dystrophy;Dystrophinopathies;Duchenne muscular dystrophy;DMD;Becker muscular dystrophy;BMD;Limb-girdle muscular dystrophy;LGMD;Congenital muscular dystrophy;CMD;Fukuyama-type congenital muscular dystrophy;FCMD;Walker-Warburg syndrome;Muscle-eye-brain disease;α-dystroglycanopathy;Integrin α7 deficient CMD;CIntegrin α7 deficient ongenital muscular dystrophy;Merosin-deficient congenital muscular dystrophy;Ullrich congenital muscular dystrophy;Laminopathy;Rigid spine syndrome;Dynamin 2 deficient congenital muscular dystrophy;Telesonin-deficient congenital muscular dystrophy;Congenital muscular dystrophy with mitochondrial structural abnormalities;Facioscapulohumeral muscular dystrophy;FSMD;Myotonic dystrophy;Dystrophia myotonica;DM;Emery-Dreifuss muscular dystrophy;EDMD;Oculopharyngeal muscular dystrophy;OPMD;Myotilinopathy;Caveolinopathy;Limb gridle muscular dystrophy 1C;LGMD1C;Desminopathy;Sarcoglycanopathy; 164 Oculocutaneous albinism;Hermansky-Pudlak syndrome;HPS;Chediak-Higashi syndrome;Chédiak-Higashi syndrome;CHS;Griscelli syndrome; 256 Muscle glycogenosis;Muscular glycogenosis;Muscle glycogen storage disease;Muscular glycogen storage disease;Glycogen storage disease type 0;GSD0;Glycogen synthase deficiency;Glycogen storage disease type II;GSDII;Pompe disease;Alpha-1,4-glucosidase acid deficiency;Glycogen storage disease type III;GSDIII;Cori disease;Forbes disease;Glycogen debranching enzyme deficiency;Glycogen storage disease type IV;GSDIV;Andersen disease;Glycogen-branching enzyme deficiency;GBED;Glycogen storage disease type V;GSDV;McArdle disease;Muscle phosphorylase deficiency;Muscular phosphorylase deficiency;Glycogen storage disease type VII;GSDVII;Tarui disease;Phosphofructokinase deficiency;PFK deficiency;Glycogen storage disease type IXd;GSDIXd;Phosphorylase kinase deficiency;Phosphoglycerate kinase deficiency;PGK deficiency;Glycogen storage disease type X;GSDX;Phosphoglycerate mutase deficiency;Glycogen storage diseass type XI;GSDXI;Kanno disease;Lactate dehydrogenase deficiency;Glycogen storage diseass type XII;GSDXII;Aldolase A deficiency;Glycogen storage diseass type XIII;GSDXIII;Beta-enolase deficiency;Glycogen storage diseass type XIV;GSDXIV;Phosphoglucomutase deficiency;Glycogen storage diseass type XV;GSDXV;Glycogenin 1 deficiency; 283 Acquired pure red cell aplasia;Pure red cell aplasia; 284 Diamond-Blackfan anemia; 285 Fanconi anemia; 296 Biliary atresia; 331 Idiopathic multicentric castleman disease;iMCD;Castleman disease;
55	PI3K-Akt signaling pathway 💬	[2] IFNAR1, IFNAR2 💬 PI3K-Akt signaling pathway × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 PI3K-Akt signaling pathway × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 55. PI3K-Akt signaling pathway × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
56	PI3K-Akt signaling pathway 💬	[2] IFNAR1, IFNAR2 💬 PI3K-Akt signaling pathway × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 PI3K-Akt signaling pathway × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 56. PI3K-Akt signaling pathway × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
57	PI3K-Akt signaling pathway 💬	[1] ITGA4 💬 PI3K-Akt signaling pathway × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 PI3K-Akt signaling pathway × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 57. PI3K-Akt signaling pathway × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
58	Pyrimidine metabolism 💬	[1] DHODH 💬 Pyrimidine metabolism × Name Full Name DHODH dihydroorotate dehydrogenase (quinone)	Teriflunomide 💬 Pyrimidine metabolism × Name Other Names Teriflunomide Teriflunomide (USAN) Aubagio (TN) AUBAGIO TERIFLUNOMIDE	Teriflunomide	[4] 13, 25, 26, 63 💬 58. Pyrimidine metabolism × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 26 HTLV-1-associated myelopathy;Tropical spastic paraparesis;HTLV-1;HTLV-I;HAM; 63 Idiopathic thrombocytopenic purpura;Primary immune thrombocytopenia;Immune thrombocytopenic purpura;
59	Regulation of actin cytoskeleton 💬	[1] ITGA4 💬 Regulation of actin cytoskeleton × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Regulation of actin cytoskeleton × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 59. Regulation of actin cytoskeleton × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;
60	T cell receptor signaling pathway 💬	[1] PDCD1 💬 T cell receptor signaling pathway × Name Full Name PDCD1 programmed cell death 1	Pembrolizumab 💬 T cell receptor signaling pathway × Name Other Names Pembrolizumab Pembrolizumab (USAN) Pembrolizumab (genetical recombination) (JAN) Keytruda (TN) KEYTRUDA	Pembrolizumab	[2] 25, 285 💬 60. T cell receptor signaling pathway × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 285 Fanconi anemia;
61	Toll-like receptor signaling pathway 💬	[2] IFNAR1, IFNAR2 💬 Toll-like receptor signaling pathway × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa 💬 Toll-like receptor signaling pathway × Name Other Names Interferon alfa Interferon alfa (NAMALWA) (JP18) Interferon alfa (BALL-1) (JAN) Interferon alfa (INN) OIF (TN)	Interferon alfa	[2] 25, 56 💬 61. Toll-like receptor signaling pathway × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 56 Behcet disease;Behçet disease;BD;
62	Toll-like receptor signaling pathway 💬	[2] IFNAR1, IFNAR2 💬 Toll-like receptor signaling pathway × Name Full Name IFNAR1 interferon alpha and beta receptor subunit 1 IFNAR2 interferon alpha and beta receptor subunit 2	Interferon alfa-2b 💬 Toll-like receptor signaling pathway × Name Other Names Interferon alfa-2b Interferon alfa-2b (USAN) Interferon alfa-2b (genetical recombination) (JAN) Intron A (TN)	Interferon alfa-2b	[1] 25 💬 62. Toll-like receptor signaling pathway × Disease ID Name 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal;
63	Yersinia infection 💬	[1] ITGA4 💬 Yersinia infection × Name Full Name ITGA4 integrin subunit alpha 4	Natalizumab 💬 Yersinia infection × Name Other Names Natalizumab Natalizumab (USAN/INN) Natalizumab (genetical recombination) (JAN) Tysabri (TN) TYSABRI	Natalizumab	[5] 13, 15, 25, 46, 96 💬 63. Yersinia infection × Disease ID Name 13 Multiple sclerosis;Neuromyelitis optica;Neuromyelitis optica spectrum disorder;NMOSD;Balo concentric sclerosis;Baló concentric sclerosis; 15 Inclusion body myositis; 25 Progressive multifocal leukoencephalopathy;PML;Leukoencephalopathy, progressive multifocal; 46 Malignant rheumatoid arthritis;MRA;Rheumatoid vasculitis;RV;Rheumatoid arthritis;RA;Systemic rheumatoid vasculitis;SRV; 96 Crohn disease;CD;Terminal ileitis;Inflammatory bowel disease;IBD;

Back to top